Literature DB >> 19147132

Effect of pentoxifylline on vascular endothelial growth factor C and flk-1 expression on endometrial implants in the rat endometriosis model.

Nikos F Vlahos1, Odysseas Gregoriou, Aikaterini Deliveliotou, Despoina Perrea, Athanasios Vlachos, Yulian Zhao, Joseph Lai, George Creatsas.   

Abstract

OBJECTIVE: To investigate the effects of pentoxifylline, on vascular endothelial growth factor (VEGF)-C and flk-1 expression in the rat endometriosis model.
DESIGN: Prospective, randomized, placebo-controlled study.
SETTING: Academic institution. ANIMAL(S): Twenty Wistar rats with surgically induced endometriosis. INTERVENTION(S): Animals were evaluated after surgical induction of endometriosis and random allocation to a group that received pentoxifylline and a control group that received NaCl 0.9%, for 3 weeks. At the end of the treatment period the animals were killed and the implants evaluated macroscopically as well as by immunohistochemistry. MAIN OUTCOME MEASURE(S): Morphologic changes of the endometriotic implants; and evaluation of VEGF-C and flk-1 expression by a semiquantitative analysis (HSCORE) for the intensity of immunohistochemical reactivity. RESULT(S): A significant reduction was observed in the mean volume of the endometriotic implants per animal in the treatment group as compared with the control group. There was a significant reduction not only in the mean volume of implants per animal but also in the mean number of implants per animal after treatment. By immunohistochemical evaluation (HSCORE), there was a significant reduction in VEGF-C expression after treatment in all areas examined. A significant reduction of flk-1 expression was also noted in the glandular compartment after treatment but not in the epithelial surface or stroma. CONCLUSION(S): Pentoxifylline may cause suppression of endometriotic lesions by suppressing angiogenesis through VEGF-C and flk-1 expression. Copyright 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19147132     DOI: 10.1016/j.fertnstert.2008.10.056

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  6 in total

Review 1.  Pentoxifylline for the treatment of endometriosis-associated pain and infertility.

Authors:  Alexandros Loukas Grammatis; Ektoras X Georgiou; Christian M Becker
Journal:  Cochrane Database Syst Rev       Date:  2021-08-25

2.  Endometriosis: alternative methods of medical treatment.

Authors:  Leticia Muñoz-Hernando; Jose L Muñoz-Gonzalez; Laura Marqueta-Marques; Carmen Alvarez-Conejo; Álvaro Tejerizo-García; Gregorio Lopez-Gonzalez; Emilia Villegas-Muñoz; Angel Martin-Jimenez; Jesús S Jiménez-López
Journal:  Int J Womens Health       Date:  2015-06-11

3.  Pentoxifylline decreases post-operative intra-abdominal adhesion formation in an animal model.

Authors:  Ya-Lin Yang; Meng-Tse Gabriel Lee; Chien-Chang Lee; Pei-I Su; Chien-Yu Chi; Cheng-Heng Liu; Meng-Che Wu; Zui-Shen Yen; Shyr-Chyr Chen
Journal:  PeerJ       Date:  2018-08-24       Impact factor: 2.984

4.  Effects of menstrual blood‑derived stem cells on endometrial injury repair.

Authors:  Jia Hu; Kuangyu Song; Jing Zhang; Yiqiong Zhang; Bu-Zhen Tan
Journal:  Mol Med Rep       Date:  2018-12-12       Impact factor: 2.952

Review 5.  Endometriosis-Associated Angiogenesis and Anti-angiogenic Therapy for Endometriosis.

Authors:  Monica S Chung; Sang Jun Han
Journal:  Front Glob Womens Health       Date:  2022-04-05

Review 6.  Medical treatments for endometriosis-associated pelvic pain.

Authors:  Gabriella Zito; Stefania Luppi; Elena Giolo; Monica Martinelli; Irene Venturin; Giovanni Di Lorenzo; Giuseppe Ricci
Journal:  Biomed Res Int       Date:  2014-08-07       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.